Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages

Posted by on Jul 9th, 2026

Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) has been given an average recommendation of “Buy” by the thirteen research firms that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $95.8333.

SYRE has been the topic of a number of recent research reports. Stifel Nicolaus raised their price objective on Spyre Therapeutics from $92.00 to $107.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Wedbush reiterated an “outperform” rating and set a $100.00 target price on shares of Spyre Therapeutics in a research report on Tuesday, June 16th. BTIG Research increased their target price on Spyre Therapeutics from $98.00 to $112.00 and gave the stock a “buy” rating in a report on Monday, June 15th. Robert W. Baird raised their price target on Spyre Therapeutics from $65.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Finally, JonesTrading boosted their price target on Spyre Therapeutics from $64.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, April 17th.

View Our Latest Analysis on Spyre Therapeutics

Insider Activity

In other news, insider Sheldon Sloan sold 78,333 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $71.50, for a total value of $5,600,809.50. Following the completion of the transaction, the insider directly owned 78,333 shares in the company, valued at approximately $5,600,809.50. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Michael Thomas Henderson sold 80,000 shares of the company’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $74.40, for a total transaction of $5,952,000.00. Following the sale, the director directly owned 88,606 shares of the company’s stock, valued at approximately $6,592,286.40. This trade represents a 47.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 282,500 shares of company stock valued at $21,741,101 in the last 90 days. 15.69% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Spyre Therapeutics

A number of large investors have recently modified their holdings of the business. Perceptive Advisors LLC raised its holdings in shares of Spyre Therapeutics by 149.6% during the 4th quarter. Perceptive Advisors LLC now owns 3,069,225 shares of the company’s stock worth $100,548,000 after buying an additional 1,839,780 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Spyre Therapeutics by 13,969.3% in the fourth quarter. Janus Henderson Group PLC now owns 1,829,009 shares of the company’s stock valued at $59,918,000 after buying an additional 1,816,009 shares in the last quarter. RA Capital Management L.P. bought a new position in Spyre Therapeutics in the fourth quarter valued at about $53,124,000. Remedium Capital Partners LLC acquired a new position in Spyre Therapeutics during the fourth quarter worth about $47,706,000. Finally, TCG Crossover Management LLC bought a new position in shares of Spyre Therapeutics in the third quarter worth about $18,446,000. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Stock Up 1.2%

Shares of NASDAQ:SYRE opened at $95.40 on Thursday. The company’s 50 day moving average price is $79.39 and its two-hundred day moving average price is $55.18. Spyre Therapeutics has a 12-month low of $14.51 and a 12-month high of $102.06. The firm has a market cap of $8.39 billion, a PE ratio of -45.87 and a beta of 3.02.

Spyre Therapeutics (NASDAQ:SYRE – Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). On average, research analysts expect that Spyre Therapeutics will post -2.86 EPS for the current year.

Spyre Therapeutics Company Profile

(Get Free Report)

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.

Featured Articles

Analyst Recommendations for Spyre Therapeutics (NASDAQ:SYRE)

Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.